ImmunoGen Inc (IMGN) Stock
IMGN is no longer traded. ImmunoGen was acquired by AbbVie (ABBV) on February 12, 2024.
Each IMGN share was exchanged for $31.26 in cash. Prices on this page are historical; the last trade was February 8, 2024 at $31.23.
See AbbVie (ABBV) stock →ImmunoGen stock price history
IMGN final trading statistics
- Final close
- $31.23
- Final trading day
- Feb 8, 2024
- Market cap at delisting
- $8.72B
- Shares outstanding
- 279.35M
- Final 52-week range
- $3.60 – $31.24
- Avg. volume (final 3 mo.)
- 8,287,886
- All-time high (split-adj.)
- $43.81 · Nov 2000
- All-time low (split-adj.)
- $0.84 · Dec 1997
- Return since IPO
- +228.7%
- Beta
- 1.17
- Book value / share
- $2.11
- Price / book
- 14.78
ImmunoGen annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $287.61M | -$73.5M | — |
| FY2022 | $108.78M | -$222.9M | -$0.88 |
| FY2021 | $108.78M | -$222.9M | -$0.67 |
| FY2020 | $132.30M | -$66.7M | -$0.28 |
| FY2019 | $82.27M | -$122.1M | -$0.71 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About ImmunoGen Inc
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.
ImmunoGen stock FAQ
What happened to ImmunoGen stock?
ImmunoGen was acquired by AbbVie (ABBV) on February 12, 2024. Shareholders received $31.26 in cash for each share. IMGN stock stopped trading on the Nasdaq, with a final close of $31.23 on February 8, 2024.
What did ImmunoGen shareholders receive?
Each IMGN share was converted into $31.26 in cash. The deal was valued at about $10.1 billion.
Is IMGN stock still trading?
No. IMGN was delisted from the Nasdaq on February 12, 2024 and no longer trades on a U.S. exchange.
What was the last price of IMGN stock?
IMGN closed at $31.23 on its final trading day, February 8, 2024, for a market value of about $8.72B.
What were ImmunoGen's revenue and earnings in its last full fiscal year?
ImmunoGen reported revenue of $287.61M and net income of -$73.5M in fiscal 2023, its last full year as a public company.
When did ImmunoGen go public?
ImmunoGen Inc stock began trading on November 16, 1989.